Quidel Ortho Corp QDEL
We take great care to ensure that the data presented and summarized in this overview for QuidelOrtho Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding QDEL
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.4MShares$389 Million0.26% of portfolio
-
Carlyle Group Inc. Washington, DC8.26MShares$342 Million56.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.05MShares$250 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$202 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY4.2MShares$174 Million5.33% of portfolio
-
Invesco Ltd. Atlanta, GA2.01MShares$83 Million0.02% of portfolio
-
State Street Corp Boston, MA1.91MShares$78.9 Million0.0% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO1.88MShares$77.6 Million1.22% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.68MShares$69.4 Million0.07% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx1.61MShares$66.7 Million1.53% of portfolio
Latest Institutional Activity in QDEL
Top Purchases
Top Sells
About QDEL
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
Insider Transactions at QDEL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 11
2024
|
Brian J Blaser President and CEO |
BUY
Open market or private purchase
|
Indirect |
6,033
+50.0%
|
$247,353
$41.42 P/Share
|
Dec 01
2024
|
Michelle A. Hodges Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-0.51%
|
$3,485
$41.0 P/Share
|
Dec 01
2024
|
Michelle A. Hodges Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
238
+1.4%
|
-
|
Nov 21
2024
|
Carlyle Group Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,260,183
-100.0%
|
$289,106,405
$35.31 P/Share
|
Nov 08
2024
|
Michelle A. Hodges Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,417
-7.9%
|
$60,931
$43.75 P/Share
|
Nov 08
2024
|
Michelle A. Hodges Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,970
+18.13%
|
-
|
Oct 15
2024
|
Michelle A. Hodges Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
140
-0.99%
|
$5,600
$40.2 P/Share
|
Oct 15
2024
|
Michelle A. Hodges Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
390
+2.69%
|
-
|
Oct 15
2024
|
Robert Joseph Bujarski EVP & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
217
-0.48%
|
$8,680
$40.2 P/Share
|
Oct 15
2024
|
Robert Joseph Bujarski EVP & COO |
BUY
Grant, award, or other acquisition
|
Direct |
390
+0.86%
|
-
|
Sep 14
2024
|
Robert Joseph Bujarski EVP & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
177
-0.4%
|
$7,965
$45.47 P/Share
|
Sep 14
2024
|
Robert Joseph Bujarski EVP & COO |
BUY
Grant, award, or other acquisition
|
Direct |
314
+0.7%
|
-
|
Aug 09
2024
|
Carlyle Group Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
74,134
-0.45%
|
$3,039,494
$41.21 P/Share
|
Aug 08
2024
|
Carlyle Group Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
106,705
-0.32%
|
$4,268,200
$40.12 P/Share
|
Aug 07
2024
|
Carlyle Group Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
78,180
-0.46%
|
$3,049,020
$39.97 P/Share
|
Aug 06
2024
|
Carlyle Group Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
86,972
-0.51%
|
$3,478,880
$40.06 P/Share
|
Aug 05
2024
|
Carlyle Group Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
118,172
-0.34%
|
$4,726,880
$40.09 P/Share
|
Aug 02
2024
|
Carlyle Group Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
169,467
-0.38%
|
$6,948,147
$41.5 P/Share
|
Aug 01
2024
|
Carlyle Group Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
234,935
-0.65%
|
$9,632,335
$41.06 P/Share
|
Jul 31
2024
|
Carlyle Group Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
164,877
-0.89%
|
$6,265,326
$38.97 P/Share
|
Last 12 Months Summary
Open market or private purchase | 8.18K shares |
---|---|
Grant, award, or other acquisition | 115K shares |
Exercise of conversion of derivative security | 12.4K shares |
Payment of exercise price or tax liability | 41.6K shares |
---|---|
Open market or private sale | 12.5M shares |